Reversible Cardiomyopathy after Rituximab Treatment in a Chronic Lymphocytic Leukemia Patient
Nishat Girkar1, Saba Zaki1, Sunita Pawar2
1Department of Clinical Pharmacy, 76012Poona College of Pharmacy, Bharati Vidyapeeth University, Pune, Maharashtra, India.
Introduction:
Rituximab is a monoclonal antibody that has shown efficacy in non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), both as a single agent and in combination with traditional chemotherapies.
Case Report:
Here, we present a case wherein a 56-year-old man developed dilated cardiomyopathy following one cycle of rituximab and bendamustine chemotherapy protocol used to treat chronic lymphocytic leukemia. On the fifth day the patient developed hypotensive shock followed closely by the development of cough after two days.
Management And Outcome:
The patient was started on carvedilol 3.125 mg, ramipril 2.5 mg, and torsemide 5 mg for treatment of cardiomyopathy. Blood transfusion was necessary for hypotensive shock. Antibiotic regimen was started for sepsis and progressive cough. The patient recovered fully from all the symptoms.
Discussion:
This case illustrates the potential for cardiomyopathy with rituximab, particularly in patients with chronic lymphocytic leukemia, and its proposed mechanisms and treatment. The expanding utility of rituximab impels us to increase monitoring and awareness of this serious cardiovascular adverse effect.
More Related Videos
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Rheumatic Heart Disease I: Introduction
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease IV: Nursing Management

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
